Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “BARBITURIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 793 records · Page 44Linked to original sources

[Increase of cholesterol hydroxylation in rat liver as a result of induction of microsomal enzymes].

A possibility to increase 7alpha-hydroxylation of 4-14C-cholesterol was studied in vitro, using microsomal enzymes from rat liver tissue, under effect of such inductors of these enzymes as 5-ethyl-5-phenyl barbituric acid (phenobarbital), pregnenolone-16alpha-carbonitrile, 16-dehydropregnenolone, 3-acetate-16alpha-isothiocyanogen pregnenolone. These inductors were administered per os within 5 days as an aqueous suspension, stabilized with Tween 80 at a dose 50 mg/kg daily; ethyl ester alpha-(p-chlorophenhydroxy)-isobutyric acid (klofibrate "Miskleron*) was administered at a dose of 150 mg/kg daily within 5 days. All the inductors studied increased the activity of cholesterol 7alpha-hydroxylase: pregnenolone-16alpha-carbonitrile--by 50%, 16-dehydropregnenolone--by 80%, 3-acetate-16alpha-isthiocyanogen pregnenolone--by 110% and phenobarbital--by 200%. Klofibrate did not affect the intensity of the cholesterol hydroxylation.

Animals↗

Differential biochemical response of freshly isolated rat hepatocytes to paracetamol, carbon tetrachloride and D-galactosamine toxicity.

Differential response of freshly isolated rat hepatocytes to paracetamol (acetaminophen, AAP), carbon tetrachloride (CCl4) and D-galactosamine (GalN) was examined. The viability of the cells in suspension culture was not altered for 4 hr when incubated in Hank's balanced salt solution (HBSS) supplemented with 4.2 mM NaHCO3, 10 mM HEPES buffer and 0.5% bovine serum albumin. AAP induced time and dose dependent depletion of GSH as an early manifestation of AAP toxicity. Hepatocytes exposed to AAP exhibited lower lactate dehydrogenase (LDH) activity released into the medium than in controls. This was due to the interaction of a reactive metabolite of AAP, i. e. N-acetyl p-benzoquinoneimine (NAPQI) with cell proteins. Hepatocytes isolated from rats pretreated with 3-methylcholanthrene expressed higher sensitivity to AAP toxicity at least by a factor of 5. Furthermore, AAP-induced toxicity was not found to be related to any lipoperoxidative stress. CCl4 on the other hand elicited a highly lipoperoxidative response in hepatocytes and consequent leakage of cellular enzymes with lengths of incubation. Again the sensitivity of the response to CCl4 was enhanced remarkably in hepatocytes isolated from phenobarbital- pretreated rats; LDH leakage increased by 3-fold and thio-barbituric acid reactive substances by 25-fold. Unlike the two toxicants, galactosamine depleted UDP-glucuronic acid in a concentration and time-related manners. The differential biochemical response of hepatocytes to three hepatotoxicants investigated may prove useful as rapid in vitro screen for selection of compounds of hepatoprotective potentials.

Acetaminophen↗

[The clinico-epidemiological premises for antioxidant prevention and treatment in chronic myocardial infarct].

The improvement of therapeutic and recoverable proceeding to chronic myocardial infarction (IMC) imposes a complex epidemiological estimation of the global cardiovascular risk, of their clinical and biological status. The retrospective evaluation of the risk factors (RF) by epidemiological methods, in 38 hospitalized prevalence of both constitutional and behavioral factors, and the quantification of the risk state, according to graph Euro 194, has pointed on the fact that 50% of IMC cases have presented a global risk of 10-20%. That justified the application of a preventive conduct in order to continually neutralize the associates FR. The biochemical determinations have allowed to frame the dyslipidemic patients, according to the ARCOL classification in the classes D (29.2%), E (25.0%) and B (20.8%) with direct implication in the adopted therapy. The colorimetric dozing with thyo-barbituric acid of the malonly dialdehyde (MAD) each is a product of the lipidic peroxidation, as well as the interpreting or correlation of the registered values with an evolutive clinic stage, and with the existence of some existing diseases (diabetes, chronic hepatitis etc.) along with signification of other dismethabolical parameters (cholesterol, triglycerides, LDLc, apoB) have confirmed the necessity of a complex therapy, including an antioxidative treatment, having the role to directly inhibit or exclude the free radicals resulted after the oxidative stress of the infarct.

Antioxidants↗

Enhancement of 45Ca2+ binding to acidic lipids by barbiturates, diphenylhydantoin, and ethanol.

Effects of barbiturates, diphenylhydantoin, and ethanol on 45Ca2+ binding to acidic lipids have been examined in an organic, solvent-aqueous partition system. Hexobarbital, pentobarbital, and phenobarbital, at concentrations of 0.3 and/or 0.6 mM, enhanced the binding of 45Ca2+ to phosphatidic acid, phosphatidylserine, and sulfatide but not to phosphatidylinositol or cardiolipin. Diphenylhydantoin, 0.3 mM, enhanced 45Ca2+ binding to phosphatidic acid and phosphatidylserine but not to sulfatide. Ethanol at 80 mM did not enhance 45Ca2+ binding to phosphatidic acid, but ethanol decreased the binding to cardiolipin and increased it to sulfatide.

Barbiturates↗

Pipecolic acid antagonizes barbiturate-enhanced GABA binding to bovine brain membranes.

L-Pipecolic acid, a brain L-lysine metabolite, is found to inhibit GABA binding to bovine synaptic membranes strongly in the presence of hexobarbital (IC50 = 2 X 10(-10)M) or pentobarbital (IC50 = 2 X 10(-9)M), but only slightly (less than 10%) by itself. Longer dialysis increases this binding inhibition. Hill plots indicate heterogeneity of L-pipecolic acid displaceable GABA binding sites. L-Pipecolic acid may be an endogenous ligand acting as a neuromodulator on the GABA receptor ionophore complex, or it may act on its own membrane binding sites exerting an allosteric effect on the GABA receptor complex. This discovery may be useful for further defining pharmacological and biochemical differences between the GABA receptors in the brain.

Animals↗

Reversal of the action of amino acid antagonists by barbiturates and other hypnotic drugs.

1 The effects of pentobarbitone (PB) and other sedative/hypnotic drugs have been examined in relation to gamma-aminobutyric acid (GABA) in vitro on the superfused isolated superior cervical ganglion of the rat and in vivo on single units in the brain stem of the anaesthetized rat.2 PB, and other barbiturates, depolarized the ganglion in a dose-dependent manner (threshold concentration 100-300 muM, cf. GABA depolarization threshold 1 muM). The depolarization was reduced in the presence of the selective GABA antagonist (+)-bicuculline methochloride (Bic). Other non-barbiturate sedatives e.g. chlordiazepoxide, amitriptyline, promethazine at concentrations up to 2mM produced no depolarization.3 PB, tested at concentrations up to 80 muM, produced variable effects on the dose-response curve to GABA. On most occasions a slight potentiation occurred in responses to low concentrations of GABA (below 10 muM) coupled with a depression in the responses to concentrations of GABA greater than 10 muM.4 Superfusion with PB in the presence of Bic reversed the depression in the response to GABA produced by Bic. This reversal phenomenon occurred at concentrations of PB too low to depolarize the ganglion and was dependent not only on the concentration of PB but also on that of Bic.5 The reversal potency within an homologous series of barbiturates increased with the size of the alkyl substituent (R2) at C5 on the barbiturate ring. The most potent occurred when the substituent contained 5 carbon atoms (pentobarbitone and amylobarbitone); above this, activity decreased.6 PB reversed the effects of the other GABA antagonists, tetramethylenedisulphotetramine and isopropyl bicyclophosphate and also the non-selective antagonism produced by strychnine. A concomitant reduction by strychnine of responses to the cholinomimetic, carbachol, was not reversed by PB.7 Non-barbiturate sedative/hypnotics also reversed the GABA antagonism produced by Bic. The benzodiazepines were effective at lower concentrations than PB (chlordiazepoxide threshold concentration 0.5 muM, cf. PB 5 muM), however, they only produced a partial reversal even at concentrations much higher than the maximally effective concentration of PB.8 The Bic reversal effect of chloridazepoxide (and other benzodiazepines) lasted many hours after removal from the superfusion solution. By contrast the effect of PB lasted only 15-30 min after its removal.9 Chlordiazepoxide (30 muM) applied in the absence of Bic did not affect the response to GABA but did reduce the depression produced by the subsequent application of Bic even though the chlordiazepoxide had been removed 40 min earlier.10 In the rat brain stem in vivo PB, applied iontophoretically in amounts which neither decreased the spontaneous neuronal firing rate nor affected the response to GABA or glycine, reversed the GABA antagonism induced by iontophoretic application of Bic (in all 23 neurones tested). PB also reversed the antagonism produced by strychnine of responses to glycine although this was less readily observed (5 out of 14 neurones tested).11 Iontophoretic application of other barbiturates and chlordiazepoxide also reversed the effect of Bic. Chlordiazepoxide only produced a partial reversal, as in the isolated ganglion, and no reversal could be demonstrated with flurazepam.12 Intravenous administration of thiopentone (1.3 mg/kg) pentobarbitone (0.4-5.5 mg/kg) hexobarbitone (0.4-0.8 mg/kg) and clonazepam (0.1-0.2 mg/kg) also reversed the effect of iontophoretically applied Bic. The reversal by clonazepam was of much longer duration than that produced by the barbiturates.13 It is suggested that the reversal exhibited by PB and the other hypnotics may be explained by assuming that the amino acids and their antagonists bind to the membrane at separate sites. If the reversal agent has particular affinity only for the antagonist binding site then it may displace the antagonist without affecting the receptor.

Aminobutyrates↗

Barbiturates enhance retinoic acid or 1,25-dihydroxyvitamin D3-induced differentiation of leukemia HL-60 cells.

In the presence of 1 nM retinoic acid (RA), pentobarbital markedly enhanced differentiation of HL-60 cells to granulocytic cells. In the absence of RA, pentobarbital by itself did not induce cell differentiation. Similarly, pentobarbital enhanced the action of 1,25-dihydroxyvitamin D3 to induce differentiation of HL-60 cells into monocyte/macrophage lineage. The potency of various barbiturates to enhance cell differentiation was closely correlated with their activity to inhibit protein kinase C of HL-60 cells. In contrast to staurosporine, however, barbiturates did not affect the action of differentiation inducers of other types such as dimethyl sulfoxide, dibutyryl cyclic AMP or actinomycin D.

Alkaloids↗

Comparison of the effects of a convulsant barbiturate on the release of endogenous and radiolabeled amino acids from slices of mouse hippocampus.

The convulsant barbiturate 5-(2-cyclohexylidene-ethyl)-5-ethyl barbituric acid (CHEB) stimulates the spontaneous release of endogenous and radiolabeled acetylcholine (ACh) from mouse hippocampal slices in vitro. In order to determine if the ability of CHEB to release ACh was unique to this neurotransmitter, we have studied the action of this drug in vitro on the release of both radiolabeled and endogenous putative neurotransmitter and non-transmitter amino acids in the hippocampus. Although CHEB stimulated the spontaneous release of both [3H]gamma-n-aminobutyric acid (GABA) and endogenous GABA, CHEB had different effects on the spontaneous release of radiolabeled and endogenous L-glutamate and L-aspartate: L-[3H]glutamate release was inhibited by CHEB, but endogenous L-glutamate release was unaffected by CHEB, but endogenous L-aspartate release was stimulated. The spontaneous release of the amino acids L-alanine and glycine (not thought to be neurotransmitters in the hippocampus) was not affected by CHEB. The results of this study indicate that CHEB does not always stimulate the release of all putative neurotransmitters. The ability of this drug to release ACh, GABA, and L-aspartate may be the result of some specific interaction of CHEB with nerves using these neurotransmitters in the hippocampus. In addition, the results suggest some problems that may be encountered when radiolabeled substances are used to study neurotransmitter release.

Amino Acids↗

Ion-pair HPLC study of sulfonamides, barbiturates and antiphlogistic acids on a dynamically modified silica gel stationary phase.

The behaviour of some groups of acidic drugs (barbital derivatives, sulfonamides and antiphlogistic acids) was studied with a reversed-phase ion-pair HPLC method. A methanol-water-posphate buffered (pH = 7) mobile phase containing various concentrations of cetrimide was applied on a silica gel column. The correlations between the migration and the chemical structure within the different groups of compounds are discussed. Monofunctional benzene derivatives were utilized to investigate the influence of the various functional groups in this system on the retention.

Anti-Inflammatory Agents↗